Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Infinity Pharmaceuti (INFI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 108,425
  • Shares Outstanding, K 50,430
  • Annual Sales, $ 18,720 K
  • Annual Income, $ -30,100 K
  • 36-Month Beta 2.33
  • Price/Sales 5.66
  • Price/Cash Flow 0.00
  • Price/Book 1.27

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.83 +17.49%
on 04/13/17
3.60 -40.28%
on 04/03/17
-1.22 (-36.20%)
since 03/28/17
3-Month
1.83 +17.49%
on 04/13/17
3.84 -44.01%
on 03/02/17
+0.05 (+2.38%)
since 01/27/17
52-Week
0.84 +155.95%
on 11/04/16
6.02 -64.29%
on 04/29/16
-3.82 (-63.99%)
since 04/28/16

Most Recent Stories

More News
Alkermes (ALKS) Q1 Loss Wider than Expected, Sales Miss

Alkermes plc (ALKS) reported loss of 31 cents per share (including the impact of share-based compensation expense) in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 24...

HSKA : 108.25 (+2.88%)
GALE : 0.59 (-4.84%)
INFI : 2.15 (+2.38%)
ALKS : 58.25 (+3.46%)
Glaxo (GSK) Reports In-Line Q1 Earnings, Reiterates View

GlaxoSmithKline plc's (GSK) first quarter results came roughly in line with expectations. Glaxo reported first-quarter 2017 core earnings of 62 cents per American Depositary Share (ADS), in line with...

MYL : 37.35 (-0.98%)
GRFS : 21.71 (+2.55%)
INFI : 2.15 (+2.38%)
GSK : 40.90 (+0.29%)
Alexion (ALXN) Tops Q1 Earnings, Revenues; Ups '17 View

Alexion Pharmaceuticals, Inc.'s (ALXN) first-quarter 2017 earnings (including stock-based compensation expense) of $1.20 per share compared with the year ago earnings of 76 cents. The reported figure surpassed...

HSKA : 108.25 (+2.88%)
GALE : 0.59 (-4.84%)
INFI : 2.15 (+2.38%)
ALXN : 127.78 (+0.69%)
Celgene (CELG) Tops on Q1 Earnings, Sales Miss, Raises View

Celgene's (CELG) first-quarter results were mixed, with the company beating on earnings but missing on sales.

AGIO : 49.71 (-2.36%)
CELG : 124.05 (+0.06%)
GRFS : 21.71 (+2.55%)
INFI : 2.15 (+2.38%)
Infinity Announces the Date of Its First Quarter 2017 Financial Results Conference Call and Webcast

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on Tuesday, May 9, 2017, at 4:30 p.m. ET to review its first quarter 2017 financial results and provide an update on the company....

INFI : 2.15 (+2.38%)
AbbVie (ABBV) Presents Positive Data on HCV Combination Drug

AbbVie Inc. (ABBV) announced that data from two phase III studies, EXPEDITION-1 and ENDURANCE-3, evaluating its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P) for all genotypes...

ENTA : 31.75 (+2.22%)
GRFS : 21.71 (+2.55%)
INFI : 2.15 (+2.38%)
ABBV : 65.94 (-0.20%)
Nivalis' (NVLS) Shares Down After Merger Deal with Alpine

The announcement of Nivalis Therapeutics, Inc.'s (NVLS) merger agreement with a privately-held biotechnology company, Alpine Immune Sciences, Inc. failed to excite investors.

CORT : 9.54 (+2.14%)
GRFS : 21.71 (+2.55%)
INFI : 2.15 (+2.38%)
NVLS : 2.26 (+1.80%)
Ultragenyx's Hypophosphatemia Drug Succeeds in Phase III

Ultragenyx Pharmaceutical Inc. (RARE) and its Japanese partner Kyowa Hakko Kirin Co., Ltd announced positive data from a phase III study evaluating its pipeline candidate burosumab (KRN23) in adults with...

HSKA : 108.25 (+2.88%)
GALE : 0.59 (-4.84%)
RARE : 64.39 (-0.23%)
INFI : 2.15 (+2.38%)
Why Is Infinity (INFI) Down 37.4% Since the Last Earnings Report?

Infinity (INFI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

INFI : 2.15 (+2.38%)
AMAG Files for FDA Approval of Subcutaneous Form of Makena

AMAG Pharmaceuticals, Inc. (AMAG) announced the submission of a supplemental New Drug Application (sNDA) to the FDA for the subcutaneous auto-injector form of its marketed drug Makena in the U.S.

CORT : 9.54 (+2.14%)
GRFS : 21.71 (+2.55%)
INFI : 2.15 (+2.38%)
AMAG : 24.40 (-0.81%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Falling.

See More

Business Summary

Infinity Pharmaceuticals, Inc. is an innovative cancer drug discovery and development company that is seeking to leverage its strength in small molecule drug technologies to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions.

See More

Support & Resistance

2nd Resistance Point 2.34
1st Resistance Point 2.24
Last Price 2.15
1st Support Level 2.06
2nd Support Level 1.98

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.